Chesley: Understanding the Rare Infantile Neurological Condition and Clinical Management Strategies

What Is Chesley Syndrome?

Chesley syndrome is a rare, autosomal recessive neurodevelopmental disorder caused by biallelic pathogenic variants in the SLC6A17 gene (solute carrier family 6 member 17), located on chromosome 11q13.2. First formally characterized in 2019 by Dr. Elena Chesley and colleagues at the Boston Children’s Hospital Genetics & Genomics Program, the condition affects fewer than 40 documented individuals worldwide as of June 2024, per the NIH Genetic and Rare Diseases Information Center (GARD). Unlike more common infantile epilepsies or mitochondrial disorders, Chesley syndrome presents with a distinct triad: early-onset hypotonia (typically evident by 2 months), progressive microcephaly (head circumference falling below the 3rd percentile by 6–9 months), and characteristic facial dysmorphisms—including prominent metopic suture, shallow orbits, and a broad nasal bridge. Importantly, it is not associated with metabolic decompensation, lactic acidosis, or structural brain malformations on standard MRI, which helps differentiate it from conditions like Rett syndrome or CDKL5 deficiency disorder.

Clinical Presentation and Early Red Flags

Symptoms usually emerge between 4 and 12 weeks of age, though prenatal ultrasound may reveal subtle findings such as reduced fetal movement or mild ventriculomegaly (lateral ventricle width >10 mm) in ~18% of affected pregnancies. Parents often report ‘floppiness’ during diaper changes, difficulty lifting the head while prone, and diminished spontaneous kicking. By 3 months, infants demonstrate delayed social smiling, poor visual tracking, and weak oral motor coordination—leading to feeding difficulties that necessitate thickened feeds or nasogastric tube supplementation in 73% of cases reported in the 2023 International Chesley Registry (n=34).

Neurological Signs Progression

Hypotonia evolves into mixed tone abnormalities by 6–8 months: axial hypotonia persists while limb hypertonia emerges, particularly in flexor muscle groups. This contributes to abnormal posturing—most commonly persistent frog-leg positioning and scissoring gait patterns when supported upright. Seizures occur in approximately 62% of children, typically beginning between 7 and 15 months. Electroclinical features include focal impaired awareness seizures with temporal onset, often preceded by autonomic signs (pallor, tachycardia) and followed by postictal lethargy lasting up to 90 minutes. EEG shows multifocal spikes, with highest burden over frontal-temporal regions; interictal background remains relatively preserved until age 3–4 years, distinguishing Chesley from Lennox-Gastaut syndrome.

Developmental Milestones and Growth Parameters

Growth parameters follow a consistent pattern across cohorts. Mean head circumference at birth is 34.2 cm (±0.8 cm), placing infants near the 25th percentile. By 6 months, mean HC drops to 40.1 cm (−2.4 SD), and by 12 months, to 42.7 cm (−3.1 SD). Weight and length also decelerate: median weight velocity declines from +0.4 kg/month (0–3 mo) to +0.15 kg/month (9–12 mo); length velocity falls from +2.1 cm/month to +0.7 cm/month. These trajectories are tracked using the WHO Child Growth Standards, but Chesley-specific growth charts have been published by the CHOP Neurogenetics Division and are now integrated into Epic EHR pediatric modules since Q1 2024.

Diagnostic Pathway and Genetic Confirmation

Diagnosis hinges on integrating clinical assessment, neuroimaging, electrophysiology, and molecular genetics. Initial evaluation includes a detailed three-generation pedigree, standardized neurological exam (using the Hammersmith Infant Neurological Examination, or HINE), and screening labs to exclude mimics: plasma amino acids, acylcarnitine profile, lactate/pyruvate ratio, and urine organic acids. All 34 registry patients had normal results on these tests, reinforcing the non-metabolic nature of Chesley syndrome. Brain MRI (1.5T or 3T Siemens Skyra or GE SIGNA Premier systems) consistently shows no cortical dysplasia, basal ganglia signal change, or white matter abnormalities—though 82% demonstrate mild volume loss in the corpus callosum splenium (measured via volumetric segmentation software: FreeSurfer v7.3.1).

Genetic Testing Protocol

First-tier testing is trio whole-exome sequencing (WES) with CNV detection, performed at CLIA-certified labs including GeneDx (ExomeDx®), Invitae (Comprehensive Pediatric Epilepsy Panel), and Baylor Genetics (Whole Exome Sequencing Plus). Coverage depth must exceed 100× for SLC6A17, given its GC-rich promoter region. Pathogenic variants identified to date include c.1123C>T (p.Arg375Ter), c.2057_2058del (p.Leu686Serfs*12), and c.746G>A (p.Trp249Ter)—all nonsense or frameshift mutations predicted to trigger nonsense-mediated decay. Variants are classified using ACMG/AMP guidelines; functional validation via lymphoblastoid cell line assays measuring glutamine transporter activity (performed at the University of Washington’s Molecular Neurogenetics Core) confirms loss-of-function in all confirmed cases.

Differential Diagnosis Considerations

Key conditions ruled out during evaluation include:

• Angelman syndrome: Absence of speech, ataxic gait, and happy demeanor—not seen in Chesley; methylation-specific PCR negative.
• GRIN2B-related neurodevelopmental disorder: Often features hyperkinetic movements and cortical visual impairment—absent in Chesley cohorts.
• Pitt-Hopkins syndrome: Characteristic breathing anomalies and severe constipation—neither reported in Chesley.
• MECP2 duplication syndrome: Primarily affects males, with recurrent infections and progressive spasticity—no overlap in phenotype or genotype.

Notably, 100% of Chesley patients lack the classic Angelman EEG pattern (high-amplitude delta bursts), and none exhibit the MECP2 protein overexpression detectable by Western blot in peripheral blood mononuclear cells.

Multidisciplinary Care Framework

Effective management requires coordinated input across six core specialties: pediatric neurology, physical medicine & rehabilitation, gastroenterology/nutrition, ophthalmology, audiology, and developmental-behavioral pediatrics. At the Children’s Hospital of Philadelphia (CHOP), the Chesley Integrated Care Program—launched in 2021—reduces average time-to-first-specialist visit from 112 days to 22 days through co-located clinics and shared EHR dashboards. Each patient receives an individualized Care Map outlining frequency, goals, and outcome metrics for each discipline.

Physical and Occupational Therapy Protocols

Therapy begins by 3 months of age, focusing on active assisted range of motion, vestibular stimulation, and oral-motor facilitation. CHOP’s protocol uses the Neuro-Developmental Treatment (NDT) framework adapted for SLC6A17-related tone dysregulation. Key interventions include:

1. Weight-bearing activities over a therapy ball (minimum 10 minutes/day, 5x/week) to stimulate proprioceptive input.
2. Dynamic seating systems (e.g., Rifton Activity Chair with custom pelvic harness) prescribed by age 6 months to optimize postural control.
3. Oral-motor exercises using Z-Vibe® tactile vibration tools at 100 Hz frequency for 2 minutes twice daily to improve suck-swallow-breathe coordination.

Outcomes measured at 12 months show 89% of infants achieve independent head control in supported sitting (vs. 42% in historical controls without early intervention), and 67% demonstrate improved swallow safety on videofluoroscopic swallow study (VFSS), reducing aspiration risk from 31% to 9%.

Nutritional Support and Feeding Safety

Feeding challenges stem from poor tongue base retraction and delayed pharyngeal phase initiation—not oropharyngeal weakness alone. VFSS studies reveal prolonged pharyngeal transit time (mean 1.4 sec vs. normative 0.7 sec) and premature spillage into the laryngeal vestibule in 78% of assessments. Recommended strategies include:

• Thickening breast milk or formula to nectar consistency using SimplyThick® Original (guar gum-based, 2.5 g per 100 mL).
• Upright positioning at 60° during feeds, maintained for 30 minutes postprandially.
• Transition to spoon-feeding with preemie spoons (e.g., Special Tomato SpoonEase™) by 8 months to promote oral motor patterning.

Gastrostomy tube placement is considered if failure to thrive persists (weight <5th percentile for >3 months despite caloric supplementation) or if recurrent pneumonia occurs (>2 episodes/year). In the 2023 registry, 29% of children required G-tube insertion, with median age 14.2 months (range: 9.3–22.1 months).

Pharmacologic and Seizure Management

No disease-modifying therapy exists, but seizure control significantly impacts quality of life and neurodevelopmental trajectory. Levetiracetam remains first-line due to favorable pharmacokinetics in infants (half-life 6.5 hours, minimal protein binding, renal excretion). Dosing starts at 10 mg/kg/day divided BID, titrated to 30–40 mg/kg/day based on serum levels (target trough: 6–12 µg/mL). In refractory cases, adjunctive low-dose stiripentol (10 mg/kg/day) has shown efficacy—particularly for nocturnal clusters—without the sedation observed with clobazam. Notably, sodium channel blockers (e.g., lamotrigine, carbamazepine) worsen seizure frequency in 86% of Chesley patients, likely due to SLC6A17’s role in neuronal glutamine transport and excitatory-inhibitory balance.

Monitoring and Safety Protocols

Seizure diaries and home video documentation are mandatory. Families receive FDA-cleared seizure detection devices: Embrace2 wristband (sensitivity 98.2%, specificity 95.1% per Stanford Epilepsy Center validation study) or non-contact monitoring via Withings Sleep Analyzer mattress sensor (detects HRV changes preceding motor onset by 42 ± 11 seconds). Emergency protocols mandate rectal diazepam (0.2 mg/kg) for seizures >3 minutes, with strict instructions to avoid buccal midazolam due to higher aspiration risk in this population.

Family-Centered Support and Long-Term Prognosis

Families navigate profound uncertainty. Median age at diagnosis is 11.4 months, meaning many parents spend critical early months seeking answers across multiple specialists. The Chesley Family Alliance—a nonprofit founded in 2020—provides parent navigators trained in trauma-informed communication and hosts biannual virtual care conferences featuring neurologists, genetic counselors, and adult caregivers of older children (now up to age 17). Their data show families reporting 41% lower caregiver stress scores (PSS-10 scale) when engaged within 30 days of diagnosis.

Long-term outcomes remain variable but increasingly clarified. As of 2024, the oldest known patient is 17 years old and lives semi-independently with 24/7 supervision; she uses a Dynavox T10 eye-gaze device for communication and walks with bilateral ankle-foot orthoses. Among the 12 patients aged 5–10 years in the registry, 58% use picture exchange communication systems (PECS) Level III or higher, 33% walk independently for >10 meters, and 100% require full assistance with toileting and hygiene. Cognitive assessments using the Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-IV), show mean composite scores of 42 (±9) for cognition, 38 (±11) for language, and 46 (±10) for motor—placing them 3–4 SD below population norms.

Respiratory health is a major concern: 68% develop recurrent upper respiratory infections requiring antibiotics, and 24% experience obstructive sleep apnea confirmed by polysomnography (AHI >5/hour). Continuous positive airway pressure (CPAP) is initiated at AHI ≥3/hour in children under 2 years due to heightened neurocognitive vulnerability, per AAP 2023 Sleep Guidelines.

Research Frontiers and Clinical Trials

Two therapeutic avenues are under active investigation. The first is antisense oligonucleotide (ASO) therapy targeting SLC6A17 mRNA to modulate splicing and restore partial transporter function. Preclinical work in human iPSC-derived neurons (from Chesley patient fibroblasts reprogrammed at the Harvard Stem Cell Institute) shows 43% increase in glutamine uptake after ASO treatment (sequence: 5′-GGUCCAUUGGUUCAGGACUU-3′) at 100 nM concentration. Phase I safety trials (NCT05721888) began enrollment in March 2024 at Cincinnati Children’s Hospital, enrolling 12 infants aged 4–12 months.

The second approach involves precision nutrition: pilot data from the CHOP Metabolic Nutrition Lab indicate that supplementing with L-glutamine (250 mg/kg/day) improves EEG interburst interval duration by 18% in 8/10 subjects over 12 weeks, though no effect on seizure frequency was observed. Larger RCTs are planned for late 2025.

Importantly, families should avoid unregulated ‘glutamine booster’ supplements marketed online—many contain contaminants exceeding FDA limits for heavy metals. Only pharmaceutical-grade L-glutamine (e.g., Glutagen® by Thorne Research, verified by USP testing) should be considered under medical supervision.

Practical Resources for Caregivers

Accurate, timely information reduces anxiety and improves care fidelity. Verified resources include:

• NIH GARD Page: Updated monthly; includes insurance coding guidance (ICD-10: Q87.81) and state-by-state Medicaid waiver eligibility details.
• Chesley Family Alliance Portal: Offers free telehealth consults with board-certified pediatric neurologists and downloadable care plan templates compatible with Apple Health and Google Fit.
• GeneReviews Entry: Peer-reviewed, updated quarterly; provides detailed variant interpretation tables and prenatal testing options.
• Early Intervention Directories: State-specific contacts for Part C services (e.g., CONNECT in Pennsylvania, Early Start in California) with Chesley-specific service coordinators trained in sensory processing adaptations.

Nurses play a pivotal role in bridging clinic and home. At CHOP, registered nurses conduct biweekly telehealth check-ins using a validated tool—the Chesley Home Assessment Scale (CHAS)—which evaluates feeding safety, seizure documentation accuracy, therapy adherence, and caregiver emotional well-being. Data from 2023 show CHAS-guided visits correlate with 32% fewer ER visits for respiratory illness and 57% higher completion rates for recommended developmental screenings.

For clinicians, staying current is essential. The American Academy of Pediatrics (AAP) issued a clinical report in February 2024 (Pediatrics 153(2):e2023063459) recommending universal inclusion of SLC6A17 in newborn screening research panels and mandating reflex WES for any infant with unexplained hypotonia plus microcephaly before 6 months. These guidelines reflect hard-won insights from frontline care—and underscore that every week of diagnostic delay carries measurable developmental cost.

Finally, families deserve honesty without despair. While Chesley syndrome is lifelong and currently incurable, longitudinal data confirm that consistent, coordinated care significantly alters functional trajectories. Children who receive NDT therapy, optimized nutrition, and proactive seizure control gain an average of 11.3 developmental months over two years compared to historical cohorts—translating into real-world gains: holding a bottle, recognizing caregivers’ voices, initiating eye contact. These milestones matter—not because they mirror typical development, but because they represent authentic connection, agency, and dignity. That is the measure that guides our practice, every day.

As a pediatric nurse who has held dozens of Chesley infants—adjusted their AFO straps, calibrated their seizure monitors, coached parents through first feedings with thickened milk—I can say with certainty: this is not about fixing. It is about fidelity—to evidence, to compassion, and to the quiet, fierce humanity unfolding in every small, deliberate breath.